Activity

The increasing activity in HBP Surgery during the past years, has allowed us to develop different types of procedures apart from the conventional liver transplantion. Among them, the use of livers from non heart beating donors, as well as starting in 2000 the first adult living donor liver transplantation program in Spain. Our long term result confirm the success of this type of transplantation achieving similar survival to that obtained after conventional cadaveric liver transplantation. A 99% survival rate at one year and 78% and 70% survival rate at 5 and 10 years. Besides we have been developing complex liver surgery procedures, specifically in relation to metastatic colorectal cancer liver disease (MCLD) and Hepatocellular Carcinoma (HCC). We perfomed around 250 liver resections and 80 liver transplantations each year.
Lines of care

LIVING DONOR LIVER TRANSPLANTATION (LDLT)
Besides to the normal activity, we perform around 8-10 LDLT's each year. The usual indication is associated to Hepatitis B or C virus related problems, either Cirrhosis or Hepatocellular Carcinoma. Our group has designed an specific protocol in which extended indications beyond Milan Criteria are included. Specific care is taking in relation to the donor. Our results in the donor have been recently published and taking as the benchmarks for Major Liver Surgery.

HEPATOCELLULAR CARCINOMA
Is one of the most frequent indications for liver Surgery, as long as the liver function remains stable. It includes surveillance of patients affected of hepatitis B or C virus, local or regional treatment in terms of Radiofrequency or Microwave ablation as well as transarterial chemoembolization. Surgery remains the gold standard treatment whenever is possible. Procedures contemplates the possibility of laparoscopic segmental liver resection.

METASTATIC COLORECTAL CANCER LIVER DISEASE
Due to the high incidence in western countries of Colorectal cancer, metastatic liver disease is also one of the most important indications for liver surgery. As a reference center, the multidisciplinary approach includes a close relationship with our oncologists and radiologists in order to increase the possibility of a successful resection and recovery. This includes neoadjuvant as well as adjuvant chemotherapy, and/or portal embolization in order to increase the remnant liver volume.
The medical team is 100% dedicated to HOSPITAL. As a result, our patients are always seen by the same team of physicians and surgeons throughout the entire procedure.
Specially trained hospital nurses have extensive experience in the care of surgical or transplant patients with a nurse-to-patient ratio that is never more than 1:2.
Material resources
HOSPITAL ROOMS
DAY HOSPITAL
SPECIFICALLY ORIENTED
INTENSIVE CARE UNITHIGHLY TRAINED INTERVENTIONAL
RADIOLOGYLAST GENERATION
CUSA DISECTOR FOR LIVER SURGERYINTEGRATED OPERATING
THEATER, INCLUDING 3d LAPAROSCOPIC TOWEREXPERTISE IN ULTRASOUND
EXPLORATION AND
THERAPEUTIC PROCEDURES
RFA AND MWAINDOCYANIN GREEN
(FLUORESCENCE) IMAGING TECHNIQUESLAST GENERATION
3D ULTRASOUND SCAN
Process
For patients affected of HCC or MCCLD:· Specific Multidisciplinary Approach Evaluation. Hepatology, Interventional Radiology and Surgery |
|
Donor Evaluation:· Overall health status including psychological evaluation · Specific Liver Evaluation. Vascular and Biliary Distribution. · Sequential donor evaluation, including a transparent and strict donation process |
|
Specifically Designed and equipped Integrated Operating Theater (x2)· Performance of the transplant in parallel (independent OR's). - Right/Left Hepatic Donation/Retrieval - Patient Explant Hepatectomy and Implant |
|
Strict Postoperative Follow up at ICU and Ward |
|
Postrtansplant Long term Follow up of the donor and the patient |
|
Our results
Liver Transplantation
![]() |
105Living Donor Liver Transplantation |
Survival Rate - Patient Survival
![]() |
99%First year |
![]() |
75%For 5 years |
Survival Rate - Graft Survival
![]() |
90%First year |
![]() |
70%For 5 years |
HEPATOCELLULAR CARCINOMA
![]() |
+300HCC resected in the last ten years |
Survival Rate
![]() |
75’6%Overall Survival at 5 years |
![]() |
38’6%Disease Free Survival at 5 years |
METASTATIC COLO-RECTAL LIVER DISEASE
![]() |
+400Major Hepatectomies (2005-2015) |
Survival Rate
![]() |
56,1%Overall Survival at 5 years |
![]() |
29,6%Disease Free Survival at 5 years |
Blog
Nuevo tratamiento con láser para la epilepsia farmacorresistente
El Grupo Hospital Clínic ha incorporado recientemente a su Unidad de Epilepsia un nuevo equipo de láser intersticial, una tecnología mínimamente invasiva que sirve para, entre otras cosas, el tratamiento de aquellas epilepsias que no responden a los tratamientos farmacológicos convencionales y que suponen el 30% de todos los pacientes con epilepsia. “Con este nuevo […]
La AEMPS aprueba el uso de una terapia de CAR-T desarrollada por el Grupo Hospital Clínic para el tratamiento de un tipo de leucemia
La inmunoterapia, un enfoque en el que se usa el propio sistema inmunitario del paciente para atacar a las células tumorales, está revolucionando en los últimos años el tratamiento del cáncer. La Agencia Española del Medicamento y Productos Sanitarios (AEMPS) acaba de aprobar el uso como medicamento de ARI-0001, una terapia celular CAR-T –un tipo de inmunoterapia– […]
Un nuevo test molecular detecta alteraciones genéticas en los tumores y mejora el diagnóstico y tratamiento personalizado del cáncer
En el Grupo Hospital Clínic contamos con una nueva opción para el diagnóstico molecular del cáncer avanzado. Se trata de un nuevo test basado en tecnología de Next Generation Sequencing (NGS) que, mediante el análisis del ADN y ARN del tumor, detecta múltiples alteraciones genéticas en 52 de sus genes. Esta nueva prueba de diagnóstico […]